Unknown Manufacturer
Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
